{"id":"tazarotene-cream-0-05","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Skin irritation"},{"rate":"5-10%","effect":"Dry skin"},{"rate":"5-10%","effect":"Redness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by binding to retinoic acid receptors, which are involved in regulating cell growth and differentiation. This leads to an increase in cell turnover and a decrease in the appearance of fine wrinkles and skin discoloration.","oneSentence":"Tazarotene is a topical retinoid that modulates cell growth and differentiation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:42.256Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acne"},{"name":"Psoriasis"}]},"trialDetails":[{"nctId":"NCT06042647","phase":"PHASE4","title":"Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis","status":"COMPLETED","sponsor":"Dermatology Consulting Services, PLLC","startDate":"2023-07-13","conditions":"Psoriasis Vulgaris","enrollment":10},{"nctId":"NCT02785159","phase":"PHASE2","title":"Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2016-02","conditions":"Psoriasis","enrollment":152},{"nctId":"NCT02886702","phase":"PHASE3","title":"A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"Fougera Pharmaceuticals Inc.","startDate":"2016-09-19","conditions":"Plaque Psoriasis","enrollment":855},{"nctId":"NCT02160665","phase":"PHASE3","title":"Generic Tazarotene Cream, 0.05% for the Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"G & W Laboratories Inc.","startDate":"2014-05","conditions":"Plaque Psoriasis","enrollment":866},{"nctId":"NCT00667589","phase":"PHASE2","title":"Sorafenib-induced Hand- Foot Skin Reaction Treatment","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2008-06","conditions":"Hand-foot Skin Reaction, Rash","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tazarotene"],"phase":"phase_3","status":"active","brandName":"Tazarotene Cream 0.05%","genericName":"Tazarotene Cream 0.05%","companyName":"Fougera Pharmaceuticals Inc.","companyId":"fougera-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tazarotene is a topical retinoid that modulates cell growth and differentiation. Used for Acne, Psoriasis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}